Perspective Therapeutics (CATX) Cash & Equivalents (2010 - 2026)

Perspective Therapeutics has disclosed Cash & Equivalents across 17 years of filings, most recently posting $236.9 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 23.64% year-over-year to $236.9 million; the TTM figure through Jun 2026 stood at $236.9 million (up 23.64% YoY), while the FY2025 annual figure was $30.6 million, down 50.26% from the prior year.
• Cash & Equivalents came in at $236.9 million for Q2 2026 at Perspective Therapeutics, down from $270.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $270.9 million in Q1 2026 to a low of $9.2 million in Q4 2023.
• Average Cash & Equivalents over 5 years is $115.9 million, with a median of $60.2 million recorded in 2022.
• Year-over-year, Cash & Equivalents tumbled 69.22% in 2022 and jumped 1389.18% in 2024.
• Over 5 years, Cash & Equivalents stood at $21.0 million in 2022, then slumped by 55.99% to $9.2 million in 2023, then soared by 566.59% to $61.6 million in 2024, then slumped by 50.26% to $30.6 million in 2025, then jumped by 673.45% to $236.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $236.9 million in Q2 2026, $270.9 million in Q1 2026, and $30.6 million in Q4 2025.